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INTRODUCTION 
The oral delivery of lipophilic drugs presents a major 
challenge because of the low aqueous solubility. Lipid-
based formulations have been shown to enhance the 
bioavailability of drugs administered orally1, 2, 3, 4. Wide 
availability of lipidic excipients with specific 
characteristics offers flexibility of application with respect 
to improving the bioavailability of poorly water-soluble 
drugs and manipulating their release profiles5. 
Selfmicroemulsifying drug delivery system(SMEDDS) are 
defined as isotropic mixtures of natural or synthetic oils, 
solid or liquid surfactants, or alternatively, one or more 
hydrophilic solvents and co-solvents/surfactants that have 
a unique ability of forming fine oil-in-water (o/w) micro 
emulsions upon mild agitation followed by dilution in 
aqueous media, such as GI fluids6. 
The self emulsification process is specific to the particular 
pair of oil and surfactant, surfactant concentration, 
oil/surfactant ratio, and the temperature at which 
self‐emulsification occurs7, 8, 9. After self dispersion, the 
drug is rapidly distributed throughout the gastrointestinal 
tract as fine droplets. The large surface area enhances the 
dissolution. The emulsion globules are further solubilized 
in the gastrointestinal tract by bile fluids. The presence of 
surfactant causes enhanced absorption due to membrane 
induced permeation changes. The droplets formed are 
either positively charged or negatively charged. As the 
mucosal lining is negatively charged it was observed that 
positively charged particles penetrated deeper into the 
ileum10. A cationic emulsion has greater bioavailability 
than an anionic emulsion11, 12. Self‐Emulsifying Drug 
Delivery Systems (SEDDS) formed using surfactants of 
HLB <12 and Self‐Micro Emulsifying Drug Delivery 
Systems (SMEDDS) formed with surfactants of HLB > 12. 
Both SEDDS and SMEDDS are stable preparations and 
improve the dissolution of the drug due to increased 
surface area on dispersion. The emulsified form itself is 
readily absorbable which ensures a rapid transport of 
poorly soluble drugs into the blood. Many researchers have 
reported applications of SEDDS for delivering and 
targeting lipophilic drugs e.g., coenzyme Q1013, vitamin 
E14, halofantrine15 and cyclosporine A16. Upon per oral 
administration, these systems form fine emulsions (or 
micro-emulsions) in gastro-intestinal tract (GIT) with mild 
agitation provided by gastric mobility. Khoo et al (1988) 
demonstrated enhanced drug absorption when using long 
chain triglycerides (LCT) compared with medium chain 
triglycerides (MCT) in the SMEDDS formulations15. 
These findings are attributed to maximal stimulation of 
lymphatic transport by the LCT. Studies indicated that the 
rate of intestinal absorption of N-LCT was similar to that 
of the other Pharmacopoeial vegetable oils such as, 
sunflower, sesame and groundnut oil17; suggesting that the 
N-LCT is acceptable for human consumption and 
pharmaceutical applications. The N-LCT offers many 
other advantages such as, easy availability in large 
quantities from natural source, toxicologically safe, 
completely biocompatible and cost effective replacement 
for commercial triglycerides and modified oils. 
NEED OF SMEDDS 
Oral delivery of poorly water-soluble compounds is to pre-
dissolve the compound in a suitable solvent and fill the 
formulation into capsules. The main benefit of this 
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approach is that pre-dissolving the compound overcomes 
the initial rate limiting step of particulate dissolution in the 
aqueous environment within the GI tract. However, a 
potential problem is that the drug may precipitate out of 
solution when the formulation disperses in the GI tract, 
particularly if a hydrophilic solvent is used (e.g. 
polyethylene glycol). If the drug can be dissolved in a lipid 
vehicle there is less potential for precipitation on dilution 
in the GI tract, as partitioning kinetics will favor the drug 
remaining in the lipid droplets. Another strategy for poorly 
soluble drugs is to formulate in a solid solution using a 
water-soluble polymer to aid solubility of the drug 
compound. For example, polyvinylpyrrolidone (PVP) and 
polyethylene glycol (PEG 6000) have been used for 
preparing solid solutions with poorly soluble drugs. One 
potential problem with this type of formulation is that the 
drug may favor a more thermodynamically stable state, 
which can result in the compound crystallizing in the 
polymer matrix. Therefore the physical stability of such 
formulations needs to be assessed using techniques such as 
differential scanning calorimetry or X-ray 
crystallography18. Self-micro emulsifying drug delivery 
system is a novel approach and is being extensively used 
to enhance the solubility and bioavailability of poorly 
water soluble drugs. In addition to this, the formulated 
SMEDDS will also prevent the drug from hostile gastric 
environment which will further help in better systemic 
absorption. 
ADVANTAGES OF SMEDDS 
 Improvement in oral bioavailability 
The ability of SMEDDS to present the drug to GIT in 
solubilised and micro emulsified form (globule size 
between 1-100 nm) and subsequent increase in specific 
surface area enable more efficient drug transport through 
the intestinal aqueous boundary layer and through the 
absorptive brush border membrane leading to improved 
bioavailability. E.g. In case of halofantrine approximately 
6-8 fold increase in bioavailability of drug was reported in 
comparison to tablet formulation15. 
 Ease of manufacture and scale-up 
SMEDDS require very simple and economical 
manufacturing facilities like simple mixer with agitator 
and volumetric liquid filling equipment for large-scale 
manufacturing. This explains the interest of industry in the 
SMEDDS. 
 Reduction in inter-subject and intra-subject 
variability and food effects 
There are several drugs which show large inter-subject and 
intra-subject variation in absorption leading to decreased 
performance of drug and patient non-compliance. Food is a 
major factor affecting the therapeutic performance of the 
drug in the body. SMEDDS are a boon for such drugs. 
Several research papers specifying that, the performance of 
SMEDDS is independent of food and, SMEDDS offer 
reproducibility of plasma profile are available18. 
 Ability to deliver peptides that are prone to 
enzymatic hydrolysis in GIT 
SMEDDS are superior as compared to the other drug 
delivery systems due to their ability to deliver 
macromolecules like peptides, hormones, enzyme 
substrates and inhibitors and their ability to offer 
protection from enzymatic hydrolysis. The intestinal 
hydrolysis of prodrug by cholinesterase can be protected if 
Polysorbate 20 is emulsifier in micro emulsion 
formulation19. These systems are formed spontaneously 
without aid of energy or heating thus suitable for 
thermolabile drugs such as peptides20. 
 No influence of lipid digestion process 
Unlike the other lipid-based drug delivery systems, the 
performance of SMEDDS is not influenced by the 
lipolysis, emulsification by the bile salts, action of 
pancreatic lipases and mixed micelle formation. 
 Increased drug loading capacity 
As the solubility of poorly water soluble drugs with 
intermediate partition coefficient (2<log P>4) are typically 
low in natural lipids and much greater in amphilic 
surfactants, co surfactants and co-solvents. 
 In SMEDDS, the lipid matrix interacts readily with 
water, forming a fine particulate oil- 
in-water (o/w) emulsion. The emulsion droplets will 
deliver the drug to the gastrointestinal mucosa in the 
dissolved state readily accessible for absorption. Therefore 
increase in AUC i.e. bioavailability and C max is observed 
with many drugs when presented in SMEDDS21. 
 Fine oil droplets empty rapidly from the stomach and 
promote wide distribution of drug  throughout the 
intestinal tract and thereby minimizing irritation 
frequently encountered with extended contact of drugs 
and gut wall22. 
 When polymer is incorporated in composition of 
SMEDDS it gives prolonged release of 
medicament23. 
 SMEDDS present drugs in a small droplet size and 
well-proportioned distribution and increase the dissolution 
and permeability. Furthermore, because drugs can be 
loaded in the inner phase and delivered to the lymphatic 
system, can bypass first pass metabolism. Thus SMEDDS 
reduce the presystemic clearance in the GI mucosa and 
hepatic first-pass metabolism. 
 Selective targeting of drug(s) toward specific 
absorption window in GIT21. 
 Protection of drug(s) from the hostile environment in 
gut22. 
 Protective of sensitive drug substances. 
 Liquid or solid dosage forms 
ADVANTAGES OF SMEDDS OVER EMULSION 
 SMEDDS not only offer the same advantages of 
emulsions of facilitating the solubility of  
hydrophobic drugs, but also overcomes the drawback 
of the layering of emulsions after sitting for a long 
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time. It can be easily stored since it belongs to a 
thermodynamics stable system. 
 Microemulsions formed by the SMEDDS exhibit good 
thermodynamics stability and 
optical transparency. Droplets of microemulsion 
formed by the SMEDDS generally ranges between 2 
and 100 nm. Since the particle size is small, the total 
surface area for absorption and dispersion is 
significantly larger than that of solid dosage form and 
it can easily penetrate the gastrointestinal tract and be 
absorbed. The bioavailability of the drug is therefore 
improved. 
 SMEDDS offer numerous delivery options like can be 
filled in hard gelatin capsules or  soft gelatin capsules 
or can be formulated into tablets whereas emulsions 
can only be given as oral solutions. 
 Emulsion cannot be autoclaved as they have phase 
inversion temperature, while SMEDDS can be 
autoclaved24. 
DISADVANTAGES OF SMEDDS
25 
 Lack of good predicative in vitro models for 
assessment of the formulations. 
 This in vitro model needs further development and 
validation before its strength can be evaluated.     
 Further development will be based on in vitro - in vivo 
correlations and therefore different prototype lipid 
based formulations needs to be developed and tested 
in vivo in a suitable animal model. 
 Another is chemical instabilities of drugs and high 
surfactant concentrations in formulations 
(approximately 30-60%) which irritate GIT. 
 Moreover, volatile co solvents in the conventional 
self-microemulsifying formulations are known to 
migrate into the shells of soft or hard gelatin capsules, 
resulting in the precipitation of the lipophilic drugs. 
 The precipitation tendency of the drug on dilution may 
be higher due to the dilution effect of the hydrophilic 
solvent. 
APPLICATIONS OF SMEDDS 
 SUPERSATURABLE SMEDDS (S-SMEDDS): S-
SMEDDS formulations have been designed and 
developed to reduce the surfactant side effects and 
achieve rapid absorption of poorly soluble drugs26. 
 SOLID SMEDDS: SMEDDS are normally prepared 
as liquid dosage forms that can be administrated in 
soft gelatin capsules, which have some disadvantages 
especially in the manufacturing process. An 
alternative method is the incorporation of liquid self 
emulsifying ingredients into a powder in order to 
create a solid dosage form (tablets, capsules). A pellet 
formulation of progesterone in SMEDDS has been 
prepared by the process of extrusion spheronization to 
provide a good in vitro drug release (100% within 30 
min, T50% at 13 min). The same dose of progesterone 
(16 mg) in pellets and in the SEDDS liquid 
formulation resulted in similar AUC, C max and T 
max values27.  Applications of SMEEDS are enlisted 
in Table 1. 
FORMULATION COMPONENTS OF SMEDDS: 
 Drug 
 Oil 
 Surfactant 
 Co-surfactant 
 Co-solvent 
 Consistency Builder 
 Enzyme Inhibitors 
 Adsorbents/solidifying agents 
 Polymers 
 Other Components 
 
Oils: The oil represents one of the most important 
excipients in the SMEDDS formulation not only because it 
can solubilize the required dose of the lipophilic drug or 
facilitate self emulsification but also and mainly because it 
can increase the fraction of lipophilic drug transported via 
the intestinal lymphatic system, thereby increasing 
absorption from the GI tract depending on the molecular 
nature of the triglyceride29. Both long and medium chain 
triglyceride (LCT and MCT) oils with different degrees of 
saturation have been used for the design of self-
emulsifying formulations. Furthermore, edible oils which 
could represent the logical and preferred lipid excipient 
choice for the development of SMEDDS are not frequently 
selected due to their poor ability to dissolve large amounts 
of lipophilic drugs. Modified or hydrolyzed vegetable oils 
have been widely used since these excipients form good 
emulsification systems with a large number of surfactants 
approved for oral administration and exhibit better drug 
solubility properties. They offer formulative and 
physiological advantages and their degradation products 
resemble the natural end products of intestinal digestion. 
Novel semisynthetic medium chain derivatives, which can 
be defined as amphiphilic compounds with surfactant 
properties, are progressively and effectively replacing the 
regular medium chain triglyceride oils in the SMEDDS25. 
This is in accordance with findings of Deckelbaum (1990) 
showing that MCT is more soluble and have a higher 
mobility in the lipid/water interfaces than LCT associated 
with a more rapid hydrolysis of MCT. Almond oil, Canola 
oil, Coconut oil, Coconut oil, Corn oil, Cottonseed oil, 
Olive oil, Peanut oil, Safflower oil, Sesame oil, Shark liver 
oil, Soyabean oil, Wheat germ oil etc are the commercially 
available triglycerides30. 
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Table: 1 Applications of SMEDDS reported in literature28 
Type Of 
Delivery 
System 
DRUG OIL Surfactant Co-solvent / 
Cosurfactant 
SIGNIFICANCE 
SMEDDS Atorvastatin Labrafil, Estol 
and Isopropyl 
myristate 
Cremophore El, 
Cremophor RH 
40 
Propylene 
glycol, PEG 
400 and 
Transcutol 
Improves solubility bioavailability and 
permeability via the mucous membrane. Oral 
bioavailability increased nearly 1.5 times. 
SMEDDS Simvastatin Caproyl 90 Cremophore EL Carbitol Release rate was higher than conventional 
tablets. The oral bioavailability of SMEDDS is 
about 1.5-fold higher than conventional 
tablets. 
SMEDDS Seocalcitol Viscoleo 
(MCT), 
Sesame oil 
(LCT) 
Cremophore 
RH40 
Akoline No improvement in bioavailability. After three 
months of storage at accelerated conditions 
(40°C/75% RH), a decrease in concentration 
of 10-11% was found. Simple lipid solutions 
are better choice compared with the developed 
SMEDDS due to a slightly higher 
biovailability and better chemical stability. 
SEDDS Ontazolast mixture of 
mono-and 
diglyceri-des 
of oleic acid 
Solid,Polyglyc-
olyzed mono-di 
and triglycerides, 
Tween 80 
- Enhanced bioavailability by 7.5 drug content. 
SMEDDS Silmyrin Ethyl linoleate Tween 80 Ethyl alcohol Release was limited, incomplete and typical of 
sustained characteristics. Relative 
bioavailability dramatically enhanced in an 
average of 1.88 and 48.82 fold that of 
silymarin PEG 400 solution and suspension 
respectively. 
Self 
Emulsifying 
Pellets 
Methyl and 
propyl 
parabens 
 
Mono & 
diglycerides of 
capric and 
caprylic acids 
Tween 80 - Improved rate of drug release from the pellets. 
By applying a water insoluble polymer 
containing a water soluble plastisizer it 
reduces the rate of drug release 
SEDDS Ketoprufen Captex 200 Tween 80 Capmul MCM Silicon dioxide was used as gelling agent. As 
the concentration of silicon dioxide increases, 
it causes an increase in the droplet size and 
slows the drug diffusion. 
SEDDS Crvedilol  
 
Labrasol 
 
Labrafil M 
1944CS 
Transcutol P 
 
Improves the oral bioavailability of upto 413%  
SEDDS Itraconazole 
 
Tocopherol 
acetate 
Pluronic L64 Transcutol 
 
Greatly enhanced bioavailability without the 
influence of food. 
SNEDDS Cefpodoxim-
e proxetil 
(CFP) 
Capryol 90 Cremophor 
EL, Solutol 
HS 
Akoline High dose of CFP (130 mg) exhibited rapid 
release independent of pH of dissolution 
media. 
 
Surfactant: Surfactant molecules may be classified based 
on the nature of the hydrophilic group within the molecule. 
The four main groups of surfactants are defined as follows: 
Anionic Surfactants, where the hydrophilic group carries 
a negative charge such as carboxyl (RCOO-),sulphonate 
(RSO3-) or sulphate (ROSO3-). Examples: Potassium 
laurate, sodium lauryl sulphate. 
Cationic surfactants, where the hydrophilic group carries 
a positive charge. Example: quaternary ammonium halide. 
Ampholytic surfactants (also called zwitterionic 
surfactants) contain both a negative and a positive charge. 
Example: sulfobetaines. 
Nonionic surfactants, where the hydrophilic group carries 
no charge but derives its water solubility from highly polar 
groups such as hydroxyl or polyoxyethylene 
(OCH2CH2O). Examples: Sorbitan esters (Spans), 
polysorbates (Tweens). 
Nonionic surfactants with high hydrophilic lipophilic 
balance (HLB) values are used in formulation of 
SMEDDS. The usual surfactant strength ranges between 
30-60% w/w of the formulation in order to form a stable 
SMEDDS. Surfactants having a high HLB and 
hydrophilicity assist the immediate formation of o/w 
droplets and/or rapid spreading of the formulation in the 
aqueous media. Surfactants are amphiphilic in nature and 
they can dissolve or solubilize relatively high amount of 
hydrophobic drug compounds31. Safety is a major 
determining factor in choosing a surfactant. Emulsifiers of 
natural origin are preferred since they are considered to be 
safer than the synthetic surfactants29. However, these 
surfactants have a limited self emulsification capacity. 
Non-ionic surfactants are less toxic than ionic surfactants 
but they may lead to reversible changes in the permeability 
of the intestinal lumen32. Large amounts of surfactants may 
cause GI irritation. There is a relationship between the 
droplet size and the concentration of the surfactant being 
used. In some cases, increasing the surfactant 
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concentration could lead to droplets with smaller mean 
droplet size, this could be explained by the stabilization of 
the oil droplets as a result of the localization of the 
surfactant molecules at the oil-water interface33. On the 
other hand, in some cases the mean droplet size may 
increase with increasing surfactant concentrations
34
. This 
phenomenon could be attributed to the interfacial 
disruption elicited by enhanced water penetration into the 
oil droplets mediated by the increased surfactant 
concentration and leading to ejection of oil droplets into 
the aqueous phase35. The surfactants used in these 
formulations are known to improve the bioavailability by 
various mechanisms including: improved drug dissolution, 
increased intestinal epithelial permeability, increased tight 
junction permeability and decreased/inhibited p-
glycoprotein drug efflux.  
Co-surfactants: Generally co-surfactant of HLB value 10-
14 is used with surfactant together to decrease the 
interfacial tension to a very small even transient negative 
value. At this value the interface would expand to form 
fine dispersed droplets, and subsequently adsorb more 
surfactant until their bulk condition is depleted enough to 
make interfacial tension positive again. This process is 
known as spontaneous emulsification forms the 
microemulsion. The selection of co-surfactant and 
surfactant is crucial not only to form the formation of 
microemulsion, but also to solubilization in 
microemulsions. Other variables such as the chemical 
nature of oil, salinity and temperature are also expected to 
influence the curvature of the interfacial film. Organic 
solvents like ethanol, propylene glycol, polyethylene 
glycol suitable for oral administration may help to dissolve 
large amounts of either the hydrophilic surfactant or the 
drug in the lipid base and can act as cosurfactant in the 
microemulsion systems. Literature has been described 
alcohol and propylene glycol free self emulsifying 
microemulsions21, 36. The drugs in the alcohol free 
formulations may exhibit limited solubility. Hydrophilic 
co-surfactants are preferably alcohols of intermediate 
chain length such as hexanol, pentanol and octanol, which 
are known to reduce the oil/water interface and allow the 
spontaneous formulation of microemulsion. Examples of 
various surfactants, co-surfactants and cosolvents used in  
Commercial formulations are enlisted in Table 2.  
Co-solvents: Organic solvents and additional compounds 
suitable for oral administration are used in SMEDDS to 
enhance the solubility of therapeutic agent or triglyceride 
in the composition37. Examples; 
 Alcohols and Polyols: Such as ethanol, isopropranol, 
butanol, benzyl alcohol, ethylene glycol, propylene 
glycol, butanediols and isomers thereof, glycerol, 
pentaerythritol, sorbitol, mannitol, transcutol, 
dimethyl isosorbide, propylene glycol, polypropylene 
glycol, hydroxyprpyl methyl cellulose and other 
cellulosic polymers, cyclodextrins and its derivatives. 
 Esters of propylene glycols having average molecular 
weight of about 200 to 6000 such as tetrahydrofuryl 
alcohol, PEG ether (glycofural) or methoxy PEG. 
 Amides such as 2-pyrrolidone, 2-piperidone, 
caprolactam, N-alkylpyrrolidone, 
Nhydroxyalkylepyrrolidone, N-alkylpiperidone, 
Nalkylcaprolactam, dimethylacetamide an polyvinyl 
pyrrolidone. 
 Esters, such as ethyl propionate, tributyl citrate, acetyl 
triethyle citrate, acetyl tributyl citrate, ethylene oleate, 
ethyl caprylate, ethyl butyrate, triacetin, propylene 
glycol monoacetate, propylene glycol diacetate, -
caprolactone, -valerolactone, -butyrolactone. 
Consistency builder: Tragacanth, cetyl alcohol, stearic 
acid or beeswax can be added to alter the consistency of 
the emulsion23. 
Enzyme inhibitors: If the therapeutic agent is subject to 
enzymatic degradation, enzyme inhibitors can be added to 
the composition of SMEDDS. Enzyme inhibitors37 are; 
1) Inhibitors that are not based on amino acids. E.g. P-
aminobenzamidine, FK-448, Cosmostat mesylate, Sodium 
glycocolate. 
2) Amino acids and modified amino acids e.g. 
aminoboronine derivatives and n-acetylcysteine. 
3) Peptides and modified peptides e.g. Bacitracin, antipain, 
leupeptin, amastatin. 
4) Polypeptide protease inhibitors e.g. Apratinin, Bowman-
Birk inhibitor, Soyabeen trypsin inhibitor, Chicken egg 
white trypsin inihibitor. 
5) Complexing agent e.g. EDTA, EGTA, 1, 10 
Phenanthroline, Hydroxychinoline. 
Adsorbants/solidifying agents: This process requires very 
high amounts of solidifying aids such as cellulose, lactose 
and silicates. Nazzal et al formulated eutectic based solid 
self-nanoemulsifying drug delivery systems (SNEDDS) 
using interaction between ubiquinone and oils that formed 
wax-like paste, which was further mixed with 
copolyvidone, maltodextrin and microcrystalline cellulose 
to obtain tablets40. Solid self-emulsifying system 
comprising goat fat and Tween 65 were formulated for 
delivery of diclofenac41. But the goat fat, used as an oil 
phase, has very limited solvent capacity and the tablets 
were produced using plastic molds without application of 
compression force. With lactose and microcrystalline 
cellulose as solidifying agents, solid self-microemulsifying 
system has been formulated by using an extrusion 
spheronization technique. It is reported that transformation 
of self-emulsifying system in solid dosage forms by 
addition of large amounts of solidifying excipients42. But 
in all these studies, to obtain solids with suitable 
processing properties, the required ratio of solidifying 
excipients to selfemulsifying drug delivery system 
(SEDDS) was very high, and it seems to be practically 
infeasible for drugs having limited solubility in oil phase. 
Gelled selfemulsifying drug delivery system of ketoprofen 
has been formulated to serve as an intermediate for further 
transformation into semisolid or solid dosage forms43. 
Recently liquid self-emulsifying system of loratadine 
transformed into solid dosage form by using porous 
polystyrene beads as solidifier. But in this study the ratio 
of solidifying carrier to self-emulsifying system is low44. 
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Table: 2 Example of surfactants, co-surfactant, and co-solvent used in commercial formulations36 
Excipient Name (commercial name) Examples of commercial products in which it has been 
used 
Surfactants/co-surfactants 
 Polysorbate 20 (Tween 20) 
 Polysorbate 80 (Tween 80) 
 Sorbitan monooleate (Span 80) 
 Polyoxy-35-castor oil(Cremophor RH40) 
Polyoxy-40- hydrogenated castor oil (Cremophor RH40) 
 Polyoxyethylated glycerides (Labrafil M 2125 Cs) 
 Polyoxyethlated oleic glycerides  (Labrafil M1944 Cs) 
 D-alpha Tocopheryl polyethylene glycol 1000 succinate 
(TPGS) 
 
Co-solvents 
  Ethanol 
  Glycerin 
 
 Polypylene glycol 
 
 
 Polyethylene glycol 
 
 
Lipid ingredients 
 Corn oilmono,di,,tri-glycerides 
  
 DL-alpha-Tocopherol 
 Fractionated triglyceride of coconut oil (medium-chain 
triglyceride) 
 Fractionated triglyceride of palm seed oil (medium-chain 
triglyceride) 
 Mixture of mono-and di-glycerides of caprylic/capric acid 
 Medium chain mono-and di-glycerides 
 Corn oil 
 Olive oil 
 Oleic acid 
 Sesame oil 
  
 Hydrogenated soyabean oil 
  
 Hydrogenated vegetable oils 
 
Soyabean oil 
 Peanut oil 
 Beeswax 
 
Targretin soft gelatin capsule 
Gengraf hard gelatin capsule 
Gengraf hard gelatin capsule 
Gengraf hard gelatin capsule, Ritonavir soft gelatin capsule 
Nerol soft gelatin capsule, Ritonavir oral solution 
Sandimmune soft gelatin capsules 
Sandimmune oral solution 
Agenerage Soft gelatin capsule, Agenarage oral solution 
 
 
 
Nerol soft gelatin Capsule, Nerol Oral Solution, Gengraf 
hard gelatin Capsule, Sandimmune soft gelatin Capsule, 
Sandimmune oral solution 
Nerol soft gelatin Capsule, Sandimmune soft gelatin 
Capsules 
 
Nerol soft gelatin Capsule, Nerol Oral Solution, Lamprene 
soft gelatin capsule, Agenerage Oral solution , Gengraf 
hard gelatin capsule 
 
Targretin soft gelatin capsule, Gengraf hard gelatin 
capsule, Agenerase soft capsule, Agenerase oral solution 
Nerol soft gelatin Capsule, Nerol Oral Solution 
Nerol Oral Solution, Fortavase soft gelatin capsule 
 
Rocaltrol soft gelatin capsule, Hectrol soft gelatin capsule 
 
Rocatrol oral solution 
Avodat soft gelatin capsule 
Fortavase soft gelatin capsule 
Sandimmune soft gelatin capsule, Depakene capsule 
Sandimmune oral solution 
Ritonavir soft gelatin capsule, Norvir soft gelatin capsule 
Marinol soft gelatin capsule 
Accutane soft gelatin capsule, Vesanoid soft gelatin 
capsule 
Accutane soft gelatin capsule, Vesanoid soft gelatin 
capsule 
Accutane soft gelatin capsule 
Prometrium soft gelatin capsule 
Vesanoid soft gelatin capsule 
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Polymers: Inert polymer matrix representing from 5 to 
40% of composition relative to the weight, which is not 
ionizable at physiological pH and being capable of forming 
matrix are used for the formulation of sustained release 
SMEDDS
38
. Ping Gao et al developed new supersaturable 
selfemulsifying drug delivery system of paclitaxel by using 
hydroxypropylmethyl cellulose (HPMC) polymer as a 
precipitation inhibitor with a conventional SEDDS 
formulation. In this study it has been observed that the 
supersaturated state is prolonged by use of HPMC in the 
formulation whereas in the absence of HPMC the SEDDS 
formulation undergoes rapid precipitation, yielding a low 
paclitaxel solution concentration. The results of 
pharamacokinetic study conducted in male Sprague-Dawley 
rats shows paclitaxel SEDDS formulation with HPMC 
(Supersaturable SEDDS) shows ~10-fold higher maximum 
concentration (Cmax) and five-fold higher oral 
bioavailability than that of Taxol and SEDDS without 
HPMC orally39. 
Other components: Other components might be pH 
adjusters, flavors, and antioxidant agents. Indeed a 
characteristic of lipid products, particularly those with 
unsaturated lipids show peroxide formation with oxidation. 
Free radicals such as ROO., RO., and .OH can damage the 
drug and induce toxicity. Lipid peroxides may also be 
formed due to auto-oxidation, which increases with 
unsaturation level of the lipid molecule. Hydrolysis of the 
lipid may be accelerated due to the pH of the solution or 
from processing energy such as ultrasonic radiation. 
Lipophilic antioxidants (e.g. α-tocopherol, propyl gallate, 
ascorbyl palmitate or BHT) may therefore be required to 
stabilize the oily content of the SMEDDS. 
FORMULATION OF SMEDDS 
The novel synthetic hydrophilic oils and surfactants usually 
dissolve hydrophobic drugs to a greater extent than 
conventional vegetable oils. The addition of solvents, such 
as ethanol, PG and PEG may also contribute to the 
improvement of drug solubility in the lipid vehicle45. With a 
large variety of liquid or waxy excipients available ranging 
from oils through lipids, hydrophobic and hydrophilic 
surfactant to water soluble co solvent, there are many 
different combinations that could be formulated for 
encapsulation in hard or soft gelatin or mixture which 
disperse to give fine colloidal emulsions22. The following 
should be considered in the formulation of a SMEDDS. 
 The solubility of the drug in different oil, surfactants 
and co solvents 
 The selection of oil, surfactant and co solvent based on 
the solubility of the drug 
 Preparation of the phase diagram. 
 The preparation of SMEDDS formulation by 
dissolving the drug in a mixture of oil, surfactant and 
co solvent46. 
Ternary diagram: Pseudo ternary phase diagram is used to 
map the optimal composition range for three key excipients 
according to the resulting droplet size following 
selfemulsification, stability upon dilution and viscosity. 
Phase diagrams are useful tools to determine the number 
and types of phases, the wt% of each phase and the 
composition of each phase at a given temperature and 
composition of the system. These diagrams are three-
dimensional but are illustrated in two-dimensions for ease 
of drawing and interpretation. 
Mechanism of self-emulsification: Self emulsification 
occurs, when the entropy change occurs, dispersion is 
greater than the energy required to increase the energy 
required to increase the surface area of the dispersion9. The 
free energy of conventional emulsion formation is a direct 
function of the energy required to create a new surface 
between the two phases and can be described by the 
equation. 
G=Ni ri 2 
Where: 
G is the free energy associated with the process (ignoring 
the free energy of mixing), 
N is the number of droplets of radius r, 
is interfacial energy with time 
The two phases of the emulsion will tend to separate, in 
order to reduce the interfacial area and subsequently, the 
free energy of the system. Therefore, the emulsions 
resulting from aqueous dilution are stabilized by 
conventional emulsifying agents, which form a monolayer 
around the emulsion droplets and hence, reduce the 
interfacial energy, as well as providing a barrier to 
coalescence47. In case of self-emulsifying system, the free 
energy required to form the emulsion is either very low or 
positive or negative then, the emulsion process occurs 
spontaneously48. Emulsification require very little input 
energy, involves destabilization through contraction of local 
interfacial regions. For emulsification to occur, it is 
necessary for the interfacial structure to have no resistance 
to surface shearing30. In earlier work it was suggested that 
the case of emulsification could be associated with the ease 
by which water penetrates into the various liquid crystal or 
phases get formed on the surface of the droplet7. The 
addition of a binary mixture (oil/non-ionic surfactant) to the 
water results in the interface formation between the oil and 
aqueous continuous phases, followed by the solubilization 
of water within the oil phase owing to aqueous penetration 
through the interface, which occurs until the solubilization 
limit is reached close to the interface8. Further aqueous 
penetration will result in the formation of the dispersed 
liquid crystalline phase. As the aqueous penetration 
proceeds, eventually all materials close to the interface will 
be liquid crystal, the actual amount depending on the 
surfactant concentration in the binary mixture once formed, 
rapid penetration of water into the aqueous cores, aided by 
the gentle agitation of the self emulsification process causes 
interface disruption and droplet formation. A combination 
of particle size analysis and low frequency dielectric 
spectroscopy was used to examine self-emulsifying 
properties of a series of Imwitor 742 (a mixture of mono-
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and diglycerides of Caprylic acids/Tween 80) systems, 
which provided evidence that the formation of the emulsion 
may be associated with liquid crystal formation, although 
the relationship was clearly complex48. The presence of the 
drug may alter the emulsion characteristics, possibly by 
interacting with the liquid crystal phase. The droplet 
structure can pass from a reversed spherical droplet to a 
reversed rod-shaped droplet, hexagonal phase, lamellar 
phase, cubic phase or other structures until, after 
appropriate dilution, a spherical droplet will be formed 
again. 
CHARACTERIZATION OF SMEDDS 
 Particle size: The droplet size of the emulsion is a 
crucial factor because it determines the rate and extent of 
drug release as well as absorption. Photon correlation 
spectroscopy (PCS) is a useful method for determination of 
emulsion droplet size especially when the emulsion 
properties do not change upon infinite aqueous dilution, a 
necessary step in this method50. 
 Polarity: Emulsion droplet polarity is also a very 
important factor in characterizing emulsification efficiency. 
The HLB, chain length, degree of unsaturation of the fatty 
acid, molecular weight of the hydrophilic portion and 
concentration of the emulsifier have an impact on the 
polarity of the oil droplets. Polarity represents the affinity 
of the drug compound for oil and/or water and the type of 
forces formed. Rapid release of the drug into the aqueous 
phase is promoted by polarity50. 
 Zeta potential: The charge of the oil droplets in 
conventional SMEDDS is negative due to the presence of 
free fatty acids; however, incorporation of a cationic lipid, 
such as oleylamine at a concentration range of 1.0-3%, will 
yield cationic SMEDDS. Thus, such systems have a 
positive n-potential value of about 35-45 mV15. This 
positive n-potential value is preserved following the 
incorporation of the drug compounds. 
 Drug precipitation /stability on dilution: The ability 
of SMEDDS to maintain the drug in solubilised form is 
greatly influenced by the solubility of the drug in oil phase. 
If the surfactant or co-surfactant is contributing to the 
greater extent in drug solubilisation then there could be a 
risk of precipitation, as dilution of SMEDDS will lead to 
lowering of solvent capacity of the surfactant or co-
surfactant, hence it is very important to determine stability 
of the system after dilution. This is usually done by diluting 
a single dose of SMEDDS in 250ml of 0.1N HCl solution. 
This solution is observed for drug precipitation if any. 
Ideally SMEDDS should keep the drug solubilized for four 
to six hours assuming the gastric retention time of two 
hours. 
EVALUATION  
Thermodynamic stability studies: The physical stability 
of a lipid –based formulation is also crucial to its 
performance, which can be adversely affected by 
precipitation of the drug in the excipient matrix. In addition, 
poor formulation physical stability can lead to phase 
separation of the excipient, affecting not only formulation 
performance, but visual appearance as well. Furthermore, 
incompatibilities between the formulation and the gelatin 
capsules shell can lead to brittleness or deformation, 
delayed disintegration, or incomplete release of drug21. 
 Heating Cooling Cycle: Six cycles between refrigerator 
temperature (4ºC) and 45 ºC with storage at each 
temperature of not less than 48 h is studied. Those 
formulations, which are stable at these temperatures, are 
subjected to centrifugation test. 
 Centrifugation: Passed formulations are centrifuged 
thaw cycles between 21 ºC and +25 ºC with storage at 
each temperature for not less than 48 h is done at 3500 
rpm for 30 min. Those formulations that does not show 
any phase separation are taken for the freeze thaw stress 
test. 
 Freeze Thaw Cycle: Three freeze for the formulations. 
Those formulations passed this test showed good 
stability with no phase separation, creaming, or 
cracking. 
Dispersibility test: The efficiency is assessed using a 
standard USP XXII dissolution apparatus 2. One mL of 
each formulation was added to 500 mL of water at 37 ± 0.5 
ºC. A standard stainless steel dissolution paddle rotating at 
50 rpm provided gentle agitation. The in vitro performance 
of the formulations is visually assessed using the following 
grading system21: 
Grade A: Rapidly forming (within 1 min) nanoemulsion, 
having a clear or bluish appearance. 
Grade B: Rapidly forming, slightly less clear emulsion, 
having a bluish white appearance. 
Grade C: Fine milky emulsion that forms within 2 min. 
Grade D: Dull, grayish white emulsion having slightly oily 
appearance that is slow to emulsify (longer than 2 min). 
Grade E: Formulation, exhibiting either poor or minimal 
emulsification with large oil globules present on the 
surface. 
Grade A and Grade B formulation will remain as 
nanoemulsion when dispersed in GIT. While formulation 
falling in Grade C could be recommend for SEDDS 
formulation. 
Turbidimetric Evaluation: Nepheloturbidimetric 
evaluation is done to monitor growth of emulsification. 
Fixed quantity of Selfemulsifying system is added to fixed 
quantity of suitable medium (0.1N hydrochloric acid) under 
continuous stirring (50 rpm) on magnetic plate at ambient 
temperature, and the increase in turbidity is measured using 
a turbidimeter. However, since the time required for 
complete emulsification is too short, it isn’t possible to 
monitor the rate of change of turbidity (rate of 
emulsification) 48. 
Viscosity Determination: The SMEDDS system is 
generally administered in soft gelatin or hard gelatin 
capsules. So, it can be easily pourable into capsules and 
such system should not too thick to create a problem. The 
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rheological properties of the micro emulsion are evaluated 
by Brookfield viscometer43.  
Droplet Size Analysis Particle Size Measurements: The 
droplet size of the emulsions is determined by photon 
correlation spectroscopy (which analyses the fluctuations in 
light scattering due to Brownian motion of the particles) 
using a Zetasizer able to measure sizes between 10 and 
5000 nm. Light scattering is monitored at 25°C at a 90° 
angle, after external standardization with spherical 
polystyrene beads43. 
Refractive Index and Percent Transmittance: Refractive 
index and percent transmittance proved the transparency of 
formulation. The refractive index of the system is measured 
by refractometer by placing drop of solution on slide and it 
compare with water (Refractive index of water1.333). The 
percent transmittance of the system is measured at 
particular wavelength using UV-spectrophotometer keeping 
distilled water as blank. If refractive index of system is 
similar to the refractive index of water and formulation 
have percent transmittance > 99 %, then formulation has 
transparent nature. 
Electro conductivity Study: The SEDD system contains 
ionic or non-ionic surfactant, oil, and water. So, this test is 
used to measure the electroconductive nature of system. 
The electro conductivity of resultant system is measured by 
electroconductometer. 
In vitro Diffusion Study: In vitro diffusion studies are 
performed to study the release behavior of formulation 
from liquid crystalline phase around the droplet using 
dialysis technique43. 
Drug content: Drug from pre-weighed SMEDDS is 
extracted by dissolving in suitable solvent. Drug content in 
the solvent extract was analyzed by suitable analytical 
method against the standard solvent solution of drug. 
Droplet polarity: Droplet polarity and droplet size are 
important emulsion characteristics. Polarity of oil droplets 
is governed by the HLB value of oil, chain length and 
degree of unsaturation of the fatty acids, the molecular 
weight of the hydrophilic portion and concentration of the 
emulsifier. A combination of small droplets and their 
appropriate polarity (lower partition coefficient o/w of the 
drug) permit acceptable rate of release of the drug. Polarity 
of the oil droplets is also estimated by the oil/water 
partition coefficient of the lipophillic drug 9, 38. 
Sustained release: For this, dissolution study is carried out 
for SMEDDS. Drugs known to be insoluble at acidic pH 
can be made fully available when it is incorporated in 
SMEDDS38. 
Yield of the smedds: The SMEDDS formed is filtered 
from the solvent, dried in the desiccators and weighed to 
get the yield of the SMEDDS formulated per batch. 
Percentage yield can be calculated by formula48 
% recovery = W1 / W2 + W3 * 100               (1) 
Where, W1 is the weight of the SMEDDS formulated. 
                W2 weight of the drug added. 
                 W3 is the weight of the lipid and surfactant used 
as the starting material. 
 The bioavailability of some of the poorly soluble drugs is 
enhanced by SMEEDS enlisted in Table 3 and examples of 
marketed SEDDS formulations are enlisted in Table 4. 
 
Table: 3 Example of bioavailability enhancement of pooly soluble drug after administration of SMEDDS formulations51 
COMPOUND OBSERVATIONN AFTER STUDY 
Win 54954 
 
Cyclosporin 
 
Halofantrine 
Ontazolast  
Simvastatin  
Danazol 
 
Carvediol Solvent green 3 
Silymarin  
Atorvastatin 
Itraconazole 
Atovaquone 
Seocalcitol 
No difference in BA but improved reproducibility, increased C max 
Increased BA and C max and reduced T max from SMEDDS  
Increased Cmax, AUC and dose linearity and reduced food effect from SMEDDS 
Reduced intra- and inter-subject variability from SMEDDS 
Trend to higher BA from LCT SMEDDS 
BA increase of at least 10- fold from all lipid based formulations 
BA 1.5 fold higher from SMEDDS 
BA from LCT solution and LC-SMEDDS 7- fold and 6- fold higher than that from 
MC-SMEDDS 
BA 1.7-fold higher from SMEDDS 
BA approximately 2-and 50- fold higher from SMEDDS 
BA significantly increased from all SMEDDS 
Increased BA and reduced food effect 
BA 3-fold higher from SMEDDS 
BA LC-SMEDDS=MC-SMEDDS 
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Table 4: Examples of marketed SEDDS formulations52 
DRUG NAME COMPOUND DOSAGE FORM COMPANY INDICATION 
Neoral® Cyclosporine A/I Soft gelatin capsule Novartis Immune suppressant 
Norvir Ritonavir® Soft gelatin capsule Abbott Laboratories HIV antiviral 
Fortovase®  Saquinavir Soft gelatin capsule Hoffmann-La Roche inc. HIV antiviral 
Agenerase®  Amprenavir Soft gelatin capsule Glaxo Smithkline HIV antiviral 
Targretin®  Bexarotene Soft gelatin capsule Ligand Antineoplastic 
Rocaltrol® Calcitriol Soft gelatin capsule Roche Calcium Regulator 
Convulex®  Valproic acid Soft gelatin capsule Pharmacia Antiepileptic 
Lipirex®  Fenofibrate Hard gelatin Capsule Genus Antihyperlipoproteinemic 
Sandimmune®  Cyclosporine A/II Soft gelatin capsule Novartis  Immuno Suppressant 
Gengraf®  Cyclosporine A/III Hard gelatin Capsule Abbott Laboratories Immuno Suppressant 
 
FACTORS AFFECTING SMEDDS 
Drug dose: Drugs, which are administered at very high 
dose, are not suitable for SMEDDS, unless they exhibit 
extremely good solubility in at least one of the components 
of SMEDDS, preferably lipophilic phase. The drugs exhibit 
limited solubility in water and lipids (typically log P values 
of approximately 2) are most difficult to deliver by 
SMEDDS. 
Drug solubility in oil phase: The ability of SMEDDS to 
maintain the drug in solubilised form is generally 
influenced by the solubility of the drug in oily phase. If the 
surfactant or co-surfactant is contributing to a greater extent 
of drug solubilization, then there could be a risk of 
precipitation, as dilution of SMEDDS will lead to lowering 
of solvent capacity of surfactant or co surfactant. 
Equilibrium solubility measurement: It can be carried out 
to anticipate potential cases of precipitation in the gut. 
However, crystallization could be slow in solubilizing 
environment of the gut. Poutons study reveals that such 
formulation can take up to 5 days to reach equilibrium and 
that the drug can remain in a super saturated state up to 24 
hours after the initial emulsification event9. 
Polarity of lipid phase: The polarity of lipid phase is one 
of the factors that govern the release from the 
microemulsion. HLB, chain length and degree of 
unsaturation of fatty acid, molecular weight of the 
lipophilic portion and concentration of the emulsifier 
govern the polarity of droplets. In fact the polarity reflects 
the affinity of the drug for oil and /or water and the type of 
forces involved. The high polarity will promote rapid rate 
of release of the drug into the aqueous phase. This is 
conformed by the observation of Sang-Cheol et al. who 
observed that the rate of release of Idebenone from 
SMEDDS is dependent upon the polarity of oil phase used. 
The highest release was obtained with the formulation that 
had oily phase with highest polarity53. 
Charge of emulsion droplets: Multiple physiological 
studies have proved that the apical potential of absorptive 
cells, as well as that of all other cells in the body, is 
negatively charged with respect to the mucosal solution in 
the lumen54. Gershanik and Benita have shown that 
positively charged emulsion droplets formed by adding 
oleylamine (OA) to appropriate SEDDS undergo 
electrostatic interaction with the CACO-2 monolayer and 
the mucosal surface of the everted rat intestine55. This 
formulation enhanced the oral bioavailability of 
progesterone in young rats. Benzoic acid had a dual 
function on the SEDDS; it could improve the self-
emulsifying performance of self-emulsifying oily 
formulations (SEOFs) and self-microemulsifying oily 
formulations (SMEOFs) in 0.1N HCl due to formation of a 
positively charged emulsion56. SMEDDS designed for the 
oral delivery of lipophilic drugs are enlisted in Table 5.
 
Table 5: Examples of smedds designed for the oral delivery of lipophilic drugs57 
Delivery system Oil Surfactant %w/w Solvent Drug compound Drug 
content 
SMEDDS - Polyglycolized glycerides 
(hlb:1-14) 
96 - Indomethacin 4 
SMEDDS (sandimmun 
neoral) 
Hydrolysed  
Corn oil 
Polyglycolized glycerides, 
POE-castor oil derivative 
Na Glycerol Csa 10 
Smedds  
(sandimmun neoral) 
Hydrolysed  
Corn oil 
Polyglycolized glycerides, 
POE-castor oil derivative 
Na Ethanol CsA 10 
SMEDDS Triglyceride maisine 35-
1, cremophore EL 58 
ethanol halofantrine 
5(lll,lml, Mlm) 
Maisine 35-1, cremophor EL 58 Ethanol Halofantrine 5 
SMEDDS Glyceryl dioleate Cremophor EL, PEG400 55-58 Ethanol Paclitaxel(±CsA) 5.7-6.25 
SMEDDS Dl-alpha tocopherol  62 Ethanol Paclitaxel 3 
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CONCLUSION 
Self-microemulsifying drug delivery systems are a 
promising approach for the formulation of drug compounds 
with poor aqueous solubility. The oral delivery of 
hydrophobic drugs can be made possible by SMEDDSs, 
which have been shown to substantially improve oral 
bioavailability and thus the dose of the drug can be reduced. 
With future development of this technology, SMEDDSs will 
continue to enable novel applications in drug delivery and 
solve problems associated with the delivery of poorly 
soluble drugs.
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